BigHat Biosciences Raises $19 Million in Series A Funding to Advance Antibody Design and Development for Safer, More Effective Treatments Andreessen Horowitz-led investment fuels hiring and R&D for AI-enabled experimental platform that speeds the antibody engineering process SAN CARLOS, Calif., February 10, 2021-- BigHat Biosciences, a novel protein therapeutics company and developer of an AI-guided antibody design platform, today announced it has raised $19 million in an oversubscribed Series A funding round, led by Andreessen Horowitz, with participation from prior investors 8VC, AME Cloud Ventures and Innovation Endeavors.